Last reviewed · How we verify
continuous pivotal βL-AB
βL-AB is a beta-lactamase inhibitor that works by inhibiting the bacterial enzyme beta-lactamase, which breaks down beta-lactam antibiotics.
βL-AB is a beta-lactamase inhibitor that works by inhibiting the bacterial enzyme beta-lactamase, which breaks down beta-lactam antibiotics. Used for Treatment of infections caused by bacteria that produce beta-lactamase enzymes, such as E. coli and Klebsiella pneumoniae.
At a glance
| Generic name | continuous pivotal βL-AB |
|---|---|
| Also known as | CID group |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | beta-lactamase inhibitor |
| Target | beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | FDA-approved |
Mechanism of action
By inhibiting beta-lactamase, βL-AB increases the effectiveness of beta-lactam antibiotics, such as penicillins and cephalosporins, against bacteria that would otherwise be resistant to these antibiotics. This is particularly useful in treating infections caused by bacteria that produce beta-lactamase enzymes.
Approved indications
- Treatment of infections caused by bacteria that produce beta-lactamase enzymes, such as E. coli and Klebsiella pneumoniae
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuous pivotal βL-AB CI brief — competitive landscape report
- continuous pivotal βL-AB updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI